Share Price:

APNASPENAspen Pharmacare Hldgs2164312 (0.06%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Aspen records 45% increase in HEPS

Aspen records 45% increase in HEPS Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded impressive interim results for the period ended December 2005. Headline earnings per share (HEPS) increased 45 percent to 86.3 cents (59.4 cents). Revenue increased by 27 percent to R1,687 billion (R1.4 billion). Operating profit rose 34 percent… Continue reading Aspen records 45% increase in HEPS

Aspen and BMS conclude strategic ARV deal

JSE listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer and the largest generic manufacturer in the southern hemisphere, has signed a non-exclusive license and technology transfer collaboration agreement with New York based Bristol-Myers Squibb (BMS) for the manufacture and distribution of a generic version of Atazanavir, a new generation anti-retroviral (ARV). BMS selected Aspen… Continue reading Aspen and BMS conclude strategic ARV deal

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.